Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy Single Center Experience of Management and Drug Rechallenge

被引:47
|
作者
Manohar, Sandhya [1 ]
Ghamrawi, Ranine [1 ]
Chengappa, Madhuri [5 ]
Goksu, Busra N. Bacik [6 ]
Kottschade, Lisa [2 ]
Finnes, Heidi [3 ]
Dronca, Roxana [7 ]
Leventakos, Konstantinos [2 ]
Herrmann, Joerg [4 ]
Herrmann, Sandra M. [1 ]
机构
[1] Mayo Clin, Div Nephrol & Hypertens, 200 First St SW, Rochester, MN 55902 USA
[2] Mayo Clin, Dept Med Oncol, Rochester, MN 55902 USA
[3] Mayo Clin, Dept Pharm, Rochester, MN 55902 USA
[4] Mayo Clin, Dept Cardiol, Rochester, MN 55902 USA
[5] Nazareth Hosp, Dept Internal Med, Philadelphia, PA USA
[6] Univ Texas Southwestern, Dept Psychiat, Dallas, TX USA
[7] Mayo Clin, Dept Med Oncol, Jacksonville, FL 32224 USA
来源
KIDNEY360 | 2020年 / 1卷 / 01期
关键词
Acute Kidney Injury and ICU Nephrology; Acute Interstitial Nephritis; Acute Kidney Injury; Biopsy; Cohort Studies; Creatinine; Immune check point-rechallenge; Immune checkpoint inhibitors; Immune-related adverse event; Immunotherapy; Kidney Function Tests; Pneumonia; Prednisone; Proton Pump Inhibitors; COMBINED NIVOLUMAB; RENAL-FUNCTION; ASSOCIATION; IPILIMUMAB; RECOVERY; FEATURES;
D O I
10.34067/KID.0000152019
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background The objective of this case cohort study was to describe our experience in the care of patients with immune checkpoint inhibitor-related acute interstitial nephritis (ICI-AIN) including rechallenge. Methods A descriptive case series of patients that received an ICI and had an AKI (defined as a >= 1.5-fold increase in serum creatinine) as an immune-related adverse event (irAE), with biopsy-proven or clinically suspected ICI-AIN from January 1, 2014 to December 1, 2018 at Mayo Clinic, Rochester. We studied details regarding diagnosis, clinical course, management, and outcomes of rechallenge of immunotherapy. Complete response (CR) was defined as return of kidney function back to baseline or < 0.3 mg/dl above baseline creatinine; partial response (PR) was defined as creatinine > 0.3 mg/dl from baseline, but less than twofold above the baseline by the end of steroid course. Results A total of 14 cases of biopsy-proven (35%) or clinically suspected (65%) ICI-AIN was identified. All patients had their ICI withheld and 12 patients received steroids. Steroid regimens were highly variable. The starting equivalent dose of prednisone was higher in those that had a CR versus a PR (median 0.77 mg/kg versus 0.66 mg/kg). Proton pump inhibitors (PPIs) were used in 11 patients and were stopped in eight (73%) patients at the time of the AKI event. A CR was seen in five (63%) of the eight patients who discontinued PPIs. Rechallenge was attempted in four of the 14 patients: three were successful with no recurrence of AKI, but one patient had recurrent AKI and fatal pneumonitis. Conclusions Careful review, withholding ICI and concomitant known AIN-inducing medications, along with prompt initial steroid management were the key in complete renal kidney recovery. A kidney biopsy should be strongly considered. Rechallenge of immunotherapy after a kidney irAE, although challenging, is possible and would need careful evaluation on an individual basis.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 50 条
  • [21] Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis
    Lin, Jamie S.
    Mamlouk, Omar
    Selamet, Umut
    Tchakarov, Amanda
    Glass, William F.
    Sheth, Rahul A.
    Layman, Rachel M.
    Dadu, Ramona
    Abdelwahab, Noha
    Abdelrahim, Maen
    Diab, Adi
    Yee, Cassian
    Abudayyeh, Ala
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [22] Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience
    Bhatlapenumarthi, Vineel
    Patwari, Anannya
    Harb, Antoine J.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (09) : 2789 - 2800
  • [23] Acute tubulointerstitial nephritis/drug induced acute kidney injury; an experience from a single center in Pakistan
    Naqvi, Rubina
    Mubarak, Muhammad
    Ahmed, Ejaz
    Akhtar, Fazal
    Naqvi, Anwar
    Rizvi, Adib
    JOURNAL OF RENAL INJURY PREVENTION, 2016, 5 (01): : 17 - 20
  • [24] Single-center Experience in Immune Checkpoint Inhibitor Therapy in advanced Squamous Cell Carcinoma
    Moussa, R.
    Mitzel-Rink, H.
    Dudda, M.
    Nikfarjam, U.
    Pawlowski, J.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 75 - 76
  • [25] PEDIATRIC CASES DIAGNOSED WITH DRUG-RELATED ACUTE TUBULOINTERSTITIAL NEPHRITIS: A SINGLE CENTER EXPERIENCE
    Simsek, Ozgur Ozdemir
    Erfidan, Gokcen
    Soyaltin, Eren
    Camlar, Secil Arslansoyu
    Mutlubas, Fatma
    Demir, Belde Kasap
    Alaygut, Demet
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3322 - 3322
  • [26] Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
    Shallis, Rory M.
    Bewersdorf, Jan Philipp
    Gowda, Lohith
    Podoltsev, Nikolai A.
    Prebet, Thomas
    Gore, Steven D.
    Halene, Stephanie
    Isufi, Iris
    Foss, Francine M.
    Huntington, Scott F.
    Kim, Tae Kon
    Pillai, Manoj M.
    Parker, Terri L.
    Neparidze, Natalia
    Bar, Noffar
    Seropian, Stuart
    Zeidan, Amer M.
    BLOOD, 2019, 134
  • [27] Acute interstitial nephritis related to immune checkpoint inhibitors
    Belliere, Julie
    Meyer, Nicolas
    Mazieres, Julien
    Ollier, Sylvie
    Boulinguez, Serge
    Delas, Audrey
    Ribes, David
    Faguer, Stanislas
    BRITISH JOURNAL OF CANCER, 2016, 115 (12) : 1457 - 1461
  • [28] Acute interstitial nephritis related to immune checkpoint inhibitors
    Julie Belliere
    Nicolas Meyer
    Julien Mazieres
    Sylvie Ollier
    Serge Boulinguez
    Audrey Delas
    David Ribes
    Stanislas Faguer
    British Journal of Cancer, 2016, 115 : 1457 - 1461
  • [29] Acute management of the endocrine complications of checkpoint inhibitor therapy
    Higham, C. E.
    Olsson-Brown, A.
    Carroll, P.
    Cooksley, T.
    Larkin, J.
    Lorigan, P.
    Morganstein, D.
    Trainer, P. J.
    ENDOCRINE CONNECTIONS, 2018, 7 (07): : G1 - G7
  • [30] A CASE OF IMMUNE-CHECKPOINT INHIBITOR MYOCARDITIS AND INTERSTITIAL NEPHRITIS
    Godding, Mark J.
    Russell, Raymond R., III
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 3598 - 3598